Summary of Significant Accounting Policies (Details 5) $ in Millions	3 Months Ended
Sep. 30, 2015 USD ($) item	Sep. 30, 2014
Segment Information
Number of operating segments	1
Recent Accounting Pronouncements
Deferred financing costs \| $	$ 5.3
Biotest \| Revenues Percentage
Collaborative Partner:
Percentages of revenue recognized	16.00%	11.00%
Lilly \| Revenues Percentage
Collaborative Partner:
Percentages of revenue recognized	35.00%	3.00%
Sanofi \| Revenues Percentage
Collaborative Partner:
Percentages of revenue recognized	0.00%	45.00%
Roche \| Revenues Percentage
Collaborative Partner:
Percentages of revenue recognized	38.00%	32.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration